{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:10:51Z","timestamp":1788120651167,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007465","name":"UiT The Arctic University of Norway","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007465","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To describe medication adherence to lipid-lowering drugs (LLDs), antihypertensive drugs, and acetylsalicylic acid (ASA) among persons with coronary heart disease (CHD) and explore its association with low-density-lipoprotein (LDL)-cholesterol, and systolic and diastolic blood pressure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Based on record linkage between the seventh wave of the Troms\u00f8 Study and the Norwegian Prescription Database, medication adherence was calculated as the proportion of days covered (PDC) for persistent prevalent users in the period of 365\u00a0days before the attendance date. Multivariable linear regression models were used to assess the association between systolic and diastolic blood pressure and medication nonadherence to antihypertensive drugs, age, sex, lifestyle, body mass index (BMI), current and previous diabetes, and between LDL-cholesterol and medication nonadherence to LLDs, age, sex, lifestyle, BMI, and current and previous diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean PDC was 0.94 for LLDs and antihypertensive drugs and 0.97 for ASA. Among persons with PDC\u2009\u2265\u20090.80 for LLDs, 12.0% had an LDL-cholesterol\u2009&lt;\u20091.8\u00a0mmol\/L. Blood pressure\u2009&lt;\u2009140\/90\u00a0mmHg (&lt;\u2009140\/80\u00a0mmHg if diabetes patient) was reached by 55.1% of those with a PDC\u2009\u2265\u20090.80 for antihypertensive drugs. Adherence to LLDs was associated with lower LDL-cholesterol, while neither systolic nor diastolic blood pressure was associated with adherence to antihypertensive drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Adherence to antihypertensive drugs, LLDs, and ASA among persons with CHD were high despite low achievement of treatment goals for blood pressure and LDL-cholesterol. There was a statistically significant association between adherence to LLDs and LDL-cholesterol, but not between adherence to antihypertensive drugs and blood pressure.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-022-03276-4","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T06:04:25Z","timestamp":1642745065000},"page":"857-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Medication adherence among persons with coronary heart disease and associations with blood pressure and low-density-lipoprotein-cholesterol"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6368-7124","authenticated-orcid":false,"given":"Elisabeth","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Primicerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell H.","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Elise","family":"Eggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate Hennie","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Waaseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"3276_CR1","doi-asserted-by":"crossref","unstructured":"Sotorra-Figuerola G, Ouchi D, Giner-Soriano M, Morros R (2021) Impact of adherence to drugs for secondary prevention on mortality and cardiovascular morbidity: A population-based cohort study. IMPACT study. Pharmacoepidemiology and drug safety.","DOI":"10.1002\/pds.5261"},{"issue":"11","key":"3276_CR2","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.1002\/clc.22056","volume":"35","author":"J Allonen","year":"2012","unstructured":"Allonen J, Nieminen MS, Lokki M, Parkkonen O, Vaara S, Perola M, Hiekkalinna T, Strandberg TE, Sinisalo J (2012) Mortality rate increases steeply with nonadherence to statin therapy in patients with acute coronary syndrome. Clin Cardiol 35(11):E22\u2013E27","journal-title":"Clin Cardiol"},{"key":"3276_CR3","doi-asserted-by":"crossref","unstructured":"Karlsson SA, Hero C, Svensson AM, Franz\u00e9n S, Miftaraj M, Gudbj\u00f6rnsdottir S, Eeg-Olofsson K, Eliasson B, Andersson Sundell K (2018) Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study. BMJ open 8(3):e020309.","DOI":"10.1136\/bmjopen-2017-020309"},{"issue":"1","key":"3276_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ahj.2013.09.014","volume":"167","author":"NK Choudhry","year":"2014","unstructured":"Choudhry NK, Glynn RJ, Avorn J, Lee JL, Brennan TA, Reisman L, Toscano M, Levin R, Matlin OS, Antman EM, Shrank WH (2014) Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J 167(1):51\u20138.e5","journal-title":"Am Heart J"},{"issue":"3","key":"3276_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","volume":"42","author":"J Schubert","year":"2021","unstructured":"Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, Ueda P, James S, Reading SR, Dluzniewski PJ, Hamer AW, Jernberg T, Hagstr\u00f6m E (2021) Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J 42(3):243\u2013252","journal-title":"Eur Heart J"},{"issue":"22","key":"3276_CR6","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103\u20132116","journal-title":"N Engl J Med"},{"key":"3276_CR7","doi-asserted-by":"crossref","unstructured":"Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European heart journal 33(13):1635\u2013701.","DOI":"10.1016\/j.atherosclerosis.2012.05.007"},{"issue":"252","key":"3276_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","volume":"2016","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corr\u00e0 U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, L\u00f8chen ML, L\u00f6llgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, Bart van der Worp H, van Dis I, Verschuren WMM (2016) European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016(252):207\u2013274","journal-title":"Atherosclerosis"},{"issue":"1","key":"3276_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"3","key":"3276_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ (2020) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41(3):407\u2013477","journal-title":"Eur Heart J"},{"issue":"1","key":"3276_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12872-021-01866-1","volume":"21","author":"E Pedersen","year":"2021","unstructured":"Pedersen E, Garcia BH, Halvorsen KH, Eggen AE, Schirmer H, Waaseth M (2021) Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Troms\u00f8 7. BMC Cardiovasc Disord 21(1):44","journal-title":"BMC Cardiovasc Disord"},{"key":"3276_CR12","doi-asserted-by":"crossref","unstructured":"Hopstock LA, Morseth B, Cook S, Eggen AE, Grimsgaard S, Lundblad MW, L\u00f8chen ML, Mathiesen E, Nilsen A, Nj\u00f8lstad I (2021) Treatment target achievement after myocardial infarction and ischaemic stroke: cardiovascular risk factors, medication use, and lifestyle: the Troms\u00f8 Study 2015\u201316. European journal of preventive cardiology.\u00a0","DOI":"10.1093\/eurjpc\/zwab050"},{"key":"3276_CR13","doi-asserted-by":"crossref","unstructured":"Aboyans V, Boukhris M (2021) Secondary prevention after an acute cardiovascular event: far from targets and large room for improvement. European journal of preventive cardiology.","DOI":"10.1093\/eurjpc\/zwab085"},{"issue":"8","key":"3276_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","volume":"26","author":"K Kotseva","year":"2019","unstructured":"Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D, Maggioni A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, Castro Conde A, Cifkova R, Crowley J, Davletov K, Deckers J, De Smedt D, De Sutter J, Dilic M, Dolzhenko M, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N, Heuschmann P, Hasan-Ali H, Jankowski P, Lalic N, Lehto S, Lovic D, Mancas S, Mellbin L, Milicic D, Mirrakhimov E, Oganov R, Pogosova N, Reiner Z, Stoerk S, Tokgozoglu L, Tsioufis C, Vulic D, Wood D (2019) Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 26(8):824\u2013835","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"3276_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/CIRCOUTCOMES.112.965665","volume":"5","author":"R Vigen","year":"2012","unstructured":"Vigen R, Shetterly S, Magid DJ, O\u2019Connor PJ, Margolis KL, Schmittdiel J, Ho PM (2012) A comparison between antihypertensive medication adherence and treatment intensification as potential clinical performance measures. Circ Cardiovasc Qual Outcomes 5(3):276\u2013282","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"3276_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/archinternmed.2007.72","volume":"168","author":"PM Ho","year":"2008","unstructured":"Ho PM, Magid DJ, Shetterly SM, Olson KL, Peterson PN, Masoudi FA, Rumsfeld JS (2008) Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med 168(3):271\u2013276","journal-title":"Arch Intern Med"},{"issue":"4","key":"3276_CR17","first-page":"e105","volume":"20","author":"MD Chi","year":"2014","unstructured":"Chi MD, Vansomphone SS, Liu IL, Cheetham C, Green KR, Scott RD, Reynolds K (2014) Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care 20(4):e105\u2013e112","journal-title":"Am J Manag Care"},{"key":"3276_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2017.05.018","volume":"263","author":"V Guglielmi","year":"2017","unstructured":"Guglielmi V, Bellia A, Pecchioli S, Della-Morte D, Parretti D, Cricelli I, Medea G, Sbraccia P, Lauro D, Cricelli C, Lapi F (2017) Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care. Atherosclerosis 263:36\u201341","journal-title":"Atherosclerosis"},{"key":"3276_CR19","doi-asserted-by":"crossref","unstructured":"Hedna K, Hakkarainen KM, Gyllensten H, J\u00f6nsson AK, Andersson Sundell K, Petzold M, H\u00e4gg S (2015) Adherence to antihypertensive therapy and elevated blood pressure: should we consider the use of multiple medications? PloS one 10(9):e0137451.","DOI":"10.1371\/journal.pone.0137451"},{"key":"3276_CR20","unstructured":"Sabat\u00e9 E (2003) Adherence to long-term therapies: evidence for action: World Health Organization."},{"issue":"4","key":"3276_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ahj.2007.12.011","volume":"155","author":"PM Ho","year":"2008","unstructured":"Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS (2008) Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155(4):772\u2013779","journal-title":"Am Heart J"},{"issue":"9","key":"3276_CR22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1185\/03007990903126833","volume":"25","author":"S Karve","year":"2009","unstructured":"Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC (2009) Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 25(9):2303\u20132310","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"3276_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691\u2013705","journal-title":"Br J Clin Pharmacol"},{"key":"3276_CR24","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2019) Guidelines for ATC classification and DDD assignment 2020. Oslo, Norway."},{"key":"3276_CR25","doi-asserted-by":"crossref","unstructured":"Dima AL, Dediu D (2017) Computation of adherence to medication and visualization of medication histories in R with AdhereR: towards transparent and reproducible use of electronic healthcare data. PloS one 12(4):e0174426.","DOI":"10.1371\/journal.pone.0174426"},{"key":"3276_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1472-6963-12-155","volume":"12","author":"WM Vollmer","year":"2012","unstructured":"Vollmer WM, Xu M, Feldstein A, Smith D, Waterbury A, Rand C (2012) Comparison of pharmacy-based measures of medication adherence. BMC Health Serv Res 12:155","journal-title":"BMC Health Serv Res"},{"key":"3276_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jclinepi.2021.02.015","volume":"135","author":"E Pedersen","year":"2021","unstructured":"Pedersen E, Truong KNL, Garcia BH, Halvorsen KH, Svendsen K, Eggen AE, Waaseth M (2021) Self-reported medication use among coronary heart disease patients showed high validity compared with dispensing data. J Clin Epidemiol 135:115\u2013124","journal-title":"J Clin Epidemiol"},{"key":"3276_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jclinepi.2018.12.003","volume":"108","author":"SD Alfian","year":"2019","unstructured":"Alfian SD, Pradipta IS, Hak E, Denig P (2019) A systematic review finds inconsistency in the measures used to estimate adherence and persistence to multiple cardiometabolic medications. J Clin Epidemiol 108:44\u201353","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"3276_CR29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/pds.4281","volume":"26","author":"SA Karlsson","year":"2017","unstructured":"Karlsson SA, Hero C, Eliasson B, Franz\u00e9n S, Svensson AM, Miftaraj M, Gudbj\u00f6rnsdottir S, Eeg-Olofsson K, Andersson SK (2017) Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: a nation-wide register-based study. Pharmacoepidemiol Drug Saf 26(10):1220\u20131232","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Pt 2","key":"3276_CR30","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.clinthera.2008.12.003","volume":"30","author":"A Helin-Salmivaara","year":"2008","unstructured":"Helin-Salmivaara A, Lavikainen P, Korhonen MJ, Halava H, Junnila SY, Kettunen R, Neuvonen PJ, Martikainen JE, Ruokoniemi P, Saastamoinen LK, Virta L, Huupponen R (2008) Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther 30(Pt 2):2228\u20132240","journal-title":"Clin Ther"},{"issue":"9","key":"3276_CR31","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1177\/2047487317693134","volume":"24","author":"J Munkhaugen","year":"2017","unstructured":"Munkhaugen J, Sverre E, Otterstad JE, Peersen K, Gjertsen E, Perk J, Gullestad L, Moum T, Dammen T, Husebye E (2017) Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol 24(9):981\u2013989","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"3276_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","volume":"2","author":"BW Karlson","year":"2016","unstructured":"Karlson BW, Wiklund O, Palmer MK, Nicholls SJ, Lundman P, Barter PJ (2016) Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother 2(4):212\u2013217","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"3276_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1741826711400545","volume":"19","author":"AK Gitt","year":"2012","unstructured":"Gitt AK, Drexel H, Feely J, Ferri\u00e8res J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, J\u00fcnger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ (2012) Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 19(2):221\u2013230","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"3276_CR34","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jash.2017.10.007","volume":"11","author":"E Sverre","year":"2017","unstructured":"Sverre E, Peersen K, Otterstad JE, Gullestad L, Perk J, Gjertsen E, Moum T, Husebye E, Dammen T, Munkhaugen J (2017) Optimal blood pressure control after coronary events: the challenge remains. J Am Soc Hypertens 11(12):823\u2013830","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"3276_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1161\/HYPERTENSIONAHA.114.03617","volume":"65","author":"Z Sun","year":"2015","unstructured":"Sun Z (2015) Aging, arterial stiffness, and hypertension. Hypertension 65(2):252\u2013256","journal-title":"Hypertension"},{"issue":"2","key":"3276_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s11096-017-0583-7","volume":"40","author":"TM Alhawassi","year":"2018","unstructured":"Alhawassi TM, Krass I, Pont LG (2018) Antihypertensive-related adverse drug reactions among older hospitalized adults. Int J Clin Pharm 40(2):428\u2013435","journal-title":"Int J Clin Pharm"},{"issue":"11","key":"3276_CR37","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00228-013-1555-z","volume":"69","author":"M Qvarnstr\u00f6m","year":"2013","unstructured":"Qvarnstr\u00f6m M, Kahan T, Kieler H, Brandt L, Hasselstr\u00f6m J, Bengtsson Bostr\u00f6m K, Manhem K, Hjerpe P, Wettermark B (2013) Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol 69(11):1955\u20131964","journal-title":"Eur J Clin Pharmacol"},{"issue":"13","key":"3276_CR38","first-page":"1183","volume":"136","author":"J Sundstr\u00f6m","year":"2017","unstructured":"Sundstr\u00f6m J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J (2017) Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide. Population-Based Cohort Study Circulation 136(13):1183\u20131192","journal-title":"Population-Based Cohort Study Circulation"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03276-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03276-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03276-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:06:41Z","timestamp":1649750801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03276-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3276"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03276-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the Regional Committee for Medical and Health Research Ethics of North Norway (2015\/1775) and had an approved Data Protection Impact Assessment (DPIA) from UiT The Arctic University of Norway.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants in the Troms\u00f8 Study have given written informed consent for their data to be used in research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}